Original post:
 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh